Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 14;136(2):224-226.
doi: 10.1111/bju.16743. Online ahead of print.

A 10-year analysis of MRI-driven prostate cancer diagnosis and active surveillance: trends and implications

Nikita Sushentsev #  1 , Rosita Comune #  2 , Kazim Ayberk Sinci  3 , Oleg Blyuss  4 , Iztok Caglič  1 , Christof Kastner  5 , Tristan Barrett  1
Affiliations

A 10-year analysis of MRI-driven prostate cancer diagnosis and active surveillance: trends and implications

Nikita Sushentsev et al. BJU Int. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The 10‐year trends of MRI‐driven prostate cancer diagnosis and AS enrolment. (A) Timeline of the introduction of MRI‐driven PCa diagnostic pathway in our centre, resulting in 5089 pre‐biopsy (Bx) MRI scans and 2580 prostate biopsies performed over the 10‐year period. (B) Longitudinal plot presenting the number of positive (PI‐RADS 3–5) and negative (PI‐RADS 1–2) MRI scans (left), along with a plot presenting the percentage of patients with positive (PI‐RADS 3–5) and negative (PI‐RADS 1–2) MRI scans who underwent prostate biopsy in our centre over the observation period (right). (C) Longitudinal plots presenting the annual rates of csPCa diagnoses per patient offered pre‐biopsy MRI (left) and per patient undergoing prostate biopsy (right). (D) Timeline of the introduction of MRI‐driven AS pathway in our centre including the AS enrolment and progression criteria, resulting in the enrolment of 1001 patients on AS over the 9‐year period; a longitudinal plot is also given, presenting the proportion of patients enrolled on AS in our centre each year who experienced AS progression within the first 12 months of follow‐up. (E) Longitudinal plots presenting the rates of patients with positive (PI‐RADS 3–5) and negative (PI‐RADS 1–2) MRI scans (left) and biopsy‐confirmed GG1 and GG2 disease (right) enrolled on AS in our centre over the observation period. (F) Longitudinal plots presenting the annual rates of AS progression in patients with positive (PI‐RADS 3–5) and negative (PI‐RADS 1–2) MRI scans (left) and biopsy‐confirmed GG1 and GG2 disease (right). P values were derived using the two‐sided z‐test comparing the relevant proportions between the pre‐pandemic (Years 1–5) and post‐pandemic (Years 7–10) observation periods. NICE, National Institute for Health and Care Excellence.
See this image and copyright information in PMC

References

    1. Barentsz JO, Richenberg J, Clements R et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22: 746–757 - PMC - PubMed
    1. Mottet N, van den Bergh RCN, Briers E et al. EAU‐EANM‐ESTRO‐ESUR‐SIOG guidelines on prostate Cancer‐2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021; 79: 243–262 - PubMed
    1. NICE . NICE Guidance: Prostate cancer: diagnosis and management. BJU Int 2019; 124: 9–26 - PubMed
    1. Mason RJ, Marzouk K, Finelli A et al. UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging. Can Urol Assoc J 2022; 16: E184–E196 - PMC - PubMed
    1. Wei JT, Barocas D, Carlsson S et al. Early detection of prostate cancer: AUA/SUO guideline part II: considerations for a prostate biopsy. J Urol 2023; 210: 54–63 - PMC - PubMed

LinkOut - more resources